본문으로 건너뛰기
← 뒤로

Development of the G-Risk scoring system utilizing inflammatory and tumor biomarkers to improve prognostic accuracy in gastric cancer patients without lymphovascular invasion.

European journal of medical research 2025 Vol.30(1) p. 308

Liu E, Xu B, Shi L, Guo H, Li C, Lv L

📝 환자 설명용 한 줄

[OBJECTIVE] This study aimed to establish the G-Risk scoring system, a prognostic model based on inflammatory and tumor biomarkers, to enhance survival predictions for gastric cancer patients without

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Liu E, Xu B, et al. (2025). Development of the G-Risk scoring system utilizing inflammatory and tumor biomarkers to improve prognostic accuracy in gastric cancer patients without lymphovascular invasion.. European journal of medical research, 30(1), 308. https://doi.org/10.1186/s40001-025-02540-4
MLA Liu E, et al.. "Development of the G-Risk scoring system utilizing inflammatory and tumor biomarkers to improve prognostic accuracy in gastric cancer patients without lymphovascular invasion.." European journal of medical research, vol. 30, no. 1, 2025, pp. 308.
PMID 40251687

Abstract

[OBJECTIVE] This study aimed to establish the G-Risk scoring system, a prognostic model based on inflammatory and tumor biomarkers, to enhance survival predictions for gastric cancer patients without lymphovascular invasion (LVI) and guide more tailored treatment strategies.

[METHODS] The key biomarkers associated with survival outcomes were identified using univariate and multivariate Cox regression analyses. These biomarkers were selected from a range of inflammatory and tumor markers to construct the G-Risk scoring system, which was specifically developed to improve prognostic accuracy in patients without LVI.

[RESULTS] The G-Risk score effectively stratified patients into high-risk and low-risk groups, achieving an AUC of 0.660, demonstrating strong predictive performance. Further multivariate analysis validated the G-Risk score as an independent prognostic factor with significant implications for patient survival.

[CONCLUSION] The G-Risk score was successfully developed and validated as a reliable prognostic tool for gastric cancer patients without LVI. Its clinical implementation offers enhanced precision in assessing prognostic risk, facilitating personalized treatment planning, improving therapeutic outcomes, and reducing unnecessary medical interventions.

MeSH Terms

Humans; Stomach Neoplasms; Prognosis; Male; Biomarkers, Tumor; Female; Middle Aged; Aged; Neoplasm Invasiveness; Inflammation; Lymphatic Metastasis; Risk Assessment